COMBINATION OF DAROLUTAMIDE WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL INCREASES SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE PHASE 3 ARASENS STUDY

被引：0
|
作者：
Olivier, Kara [1 ]
Tombal, Betrand [2 ]
Thiele, Silke [3 ]
Li, Rui [4 ]
Joensuu, Heikki [5 ]
Smith, Matthew [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Clin Univ St Luc, Brussels, Belgium
[3] Bayer AG, Berlin, Germany
[4] Bayer HealthCare Inc, Whippany, NJ USA
[5] Orion Pharma, Espoo, Finland
来源：
ONCOLOGY NURSING FORUM | 2022年 / 49卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P386
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [41] A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).
    Haresh, K. P.
    Vjaters, Egils
    Castellano, Daniel
    Olmos, David
    Shore, Neal D.
    Nevalaita, Liina
    Testa, Isabella
    Kappeler, Christian
    Kuss, Iris
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] Phase 3 Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: the ARCHES Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 10 - 12
  • [43] Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy
    Gebrael, Georges
    Sayegh, Nicolas
    Chehade, Chadi Hage
    Jo, Yeonjung
    Narang, Arshit
    Chigarira, Beverly
    Tripathi, Nishita
    Srivastava, Ayana
    Tandar, Clara
    Williams, Jessica F.
    Garg, Diya
    Ji, Richard
    Maughan, Benjamin L.
    Swami, Umang
    Agarwal, Neeraj
    PROSTATE CANCER AND PROSTATIC DISEASES, 2025,
  • [44] Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy.
    Shore, Neal D.
    Tombal, Bertrand F.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Fralich, Todd
    Li, Rui
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 166 - 166
  • [45] Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective
    Zheng, H. R.
    Wen, F.
    Wu, Y. F.
    Wheeler, J. R. C.
    Li, Q.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [46] Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
    Wu, Huina
    Sun, Lei
    Feng, Rui
    Zhang, Huiyue
    Tang, Ke
    Wang, Shuo
    Nie, Jing
    FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [47] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
    Zhuifeng Guo
    Xuwei Lu
    Fan Yang
    Liang Qin
    Ning Yang
    Jiawen Wu
    Hang Wang
    European Journal of Medical Research, 27
  • [48] Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
    Guo, Zhuifeng
    Lu, Xuwei
    Yang, Fan
    Qin, Liang
    Yang, Ning
    Wu, Jiawen
    Wang, Hang
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [49] RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS
    Saad, Fred
    Tombal, Bertrand
    Hussain, Maha
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Nordquist, Luke T.
    Tutrone, Ronald
    Shore, Neal D.
    Belkoff, Laurence
    Kapur, Shivani
    Jhaveri, Jay
    Ortiz, Jorge
    Srinivasan, Shankar
    Verholen, Frank
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2023, 209 : E380 - E380
  • [50] OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL
    Crawford, E. David
    Smith, Matthew R.
    Tombal, Bertrand
    Fizazi, Karim
    Hussain, Maha
    Sternberg, Cora N.
    Kalebasty, Arash Rezazadeh
    Tutrone, Ronald
    Shore, Neal D.
    Belkoff, Laurence
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Joensuu, Heikki
    Saad, Fred
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1038 - E1038
12345